JP2012508170A5 - - Google Patents

Download PDF

Info

Publication number
JP2012508170A5
JP2012508170A5 JP2011534731A JP2011534731A JP2012508170A5 JP 2012508170 A5 JP2012508170 A5 JP 2012508170A5 JP 2011534731 A JP2011534731 A JP 2011534731A JP 2011534731 A JP2011534731 A JP 2011534731A JP 2012508170 A5 JP2012508170 A5 JP 2012508170A5
Authority
JP
Japan
Prior art keywords
antibody
seq
tgfβrii
human
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011534731A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508170A (ja
JP5667067B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/062450 external-priority patent/WO2010053814A1/en
Publication of JP2012508170A publication Critical patent/JP2012508170A/ja
Publication of JP2012508170A5 publication Critical patent/JP2012508170A5/ja
Application granted granted Critical
Publication of JP5667067B2 publication Critical patent/JP5667067B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011534731A 2008-11-07 2009-10-29 抗tgfベータ受容体ii抗体 Expired - Fee Related JP5667067B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19869708P 2008-11-07 2008-11-07
US61/198,697 2008-11-07
US17036909P 2009-04-17 2009-04-17
US61/170,369 2009-04-17
PCT/US2009/062450 WO2010053814A1 (en) 2008-11-07 2009-10-29 Anti-tgf-beta receptor ii antibodies

Publications (3)

Publication Number Publication Date
JP2012508170A JP2012508170A (ja) 2012-04-05
JP2012508170A5 true JP2012508170A5 (enExample) 2014-04-24
JP5667067B2 JP5667067B2 (ja) 2015-02-12

Family

ID=41508691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534731A Expired - Fee Related JP5667067B2 (ja) 2008-11-07 2009-10-29 抗tgfベータ受容体ii抗体

Country Status (19)

Country Link
US (2) US8147834B2 (enExample)
EP (1) EP2356152A1 (enExample)
JP (1) JP5667067B2 (enExample)
KR (1) KR101283856B1 (enExample)
CN (1) CN102209727B (enExample)
AR (1) AR073909A1 (enExample)
AU (1) AU2009311375B2 (enExample)
BR (1) BRPI0921263A2 (enExample)
CA (1) CA2742961C (enExample)
EA (1) EA025169B1 (enExample)
IL (1) IL211842A (enExample)
JO (1) JO3096B1 (enExample)
MX (1) MX2011004871A (enExample)
NZ (1) NZ591943A (enExample)
PA (1) PA8846101A1 (enExample)
SG (1) SG10201401280TA (enExample)
TW (1) TWI384998B (enExample)
WO (1) WO2010053814A1 (enExample)
ZA (1) ZA201103178B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150651B2 (en) * 2011-01-06 2015-10-06 Glaxo Group Limited Single variable domain immunoglobulins that bind TGF-beta receptor II
AR086044A1 (es) 2011-05-12 2013-11-13 Imclone Llc Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos
PL3212225T3 (pl) 2014-10-31 2026-03-30 The Trustees Of The University Of Pennsylvania Sposoby i kompozycje zmodyfikowanych limfocytów t
AU2015380397B2 (en) 2015-01-31 2021-10-21 The Trustees Of The University Of Pennsylvania Compositions and methods for T cell delivery of therapeutic molecules
PT3370768T (pt) 2015-11-03 2022-04-21 Janssen Biotech Inc Anticorpos que se ligam especificamente ao pd-1 e seus usos
ES2951648T3 (es) 2016-03-11 2023-10-24 Scholar Rock Inc Inmunoglobulinas de unión a Tgfbeta1 y uso de las mismas
CN109844124B (zh) * 2016-05-20 2023-10-03 哈佛学院董事及会员团体 年龄相关疾病和病症的基因治疗方法
TW201825519A (zh) * 2016-10-18 2018-07-16 美商美國禮來大藥廠 TGFβ受體II抗體
CN110382530A (zh) * 2017-01-06 2019-10-25 供石公司 亚型特异性、背景许可性TGFβ1抑制剂及其用途
CN106884005A (zh) * 2017-01-19 2017-06-23 樊克兴 一种结直肠癌抗原特异性t细胞的制备方法
US10882915B2 (en) 2017-10-24 2021-01-05 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD117+ cells
EP3700568A4 (en) 2017-10-24 2021-11-10 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
WO2019084053A1 (en) * 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS
CN107973853B (zh) * 2017-12-12 2021-04-30 山西农业大学 一种利用特征多肽制备Smad2蛋白特异性抗体的方法及其应用
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
CN116199780A (zh) * 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
KR20240046905A (ko) * 2021-08-20 2024-04-11 아케소 바이오파마, 인크. 항-TIGIT 항체 및 TGF-βR을 포함하는 융합 단백질, 이의 약학 조성물, 및 용도
JP2025512025A (ja) * 2022-04-15 2025-04-16 バイオサイトジェン ファーマシューティカルズ (ベイジン) カンパニー リミテッド 抗cd40抗体及びその使用
CN116178567B (zh) * 2022-10-28 2025-01-28 四川大学华西医院 一种靶向TGFβRII的嵌合抗原受体及其用途
WO2026030756A2 (en) * 2024-08-02 2026-02-05 Salspera, Llc Liver disease treatments using attenuated strains of salmonella typhimurium

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
AU671606B2 (en) 1991-10-31 1996-09-05 Whitehead Institute For Biomedical Research TGF-beta type receptor cDNAs and uses therefor
JP2001206899A (ja) * 1999-11-18 2001-07-31 Japan Tobacco Inc TGF−βII型受容体に対するヒトモノクローナル抗体及びその医薬用途
JP2004121001A (ja) * 2002-08-07 2004-04-22 Japan Tobacco Inc TGF−βII型受容体に対する高親和性モノクローナル抗体
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo COMMON USE OF A TGF BETA SIGNAL HEMMER AND AN ANTITUMORAL AGENT

Similar Documents

Publication Publication Date Title
JP5667067B2 (ja) 抗tgfベータ受容体ii抗体
JP7273110B2 (ja) 高親和性抗vegf抗体
CN101102791B (zh) 抗血管内皮生长因子受体-1的抗体
CN117098561A (zh) Ccr8抗体及其应用
JP2021508676A (ja) 抗tigit抗体並びに治療剤及び診断剤としてのその使用
CN105829345B (zh) 结合egfr和met的多功能抗体
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
KR20220082007A (ko) 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
JP6925981B2 (ja) Vegfとnrp1との結合を阻害する抗体
WO2022068810A1 (zh) 抗Claudin18.2和CD3的双特异性抗体以及其用途
CN114786722A (zh) 抗类趋化因子受体1人源化抗体及其治疗应用
TWI413527B (zh) 抗vegfr-3抗體組合物
WO2022237819A1 (zh) 抗Siglec-15抗体及其用途
EP3777889A1 (en) Use of probdnf regulator in b cell-related diseases
CA2762446A1 (en) Use of the combination of semaphorin-4d inhibitory molecules and vegf inhibitory molecules to inhibit angiogenesis
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
KR20240022546A (ko) 항il-36r 항체 및 그의 사용
CN118580373A (zh) 一种TGF-β和TIGIT双特异性融合蛋白及其用途
CN115515637A (zh) 使用il-20拮抗剂和免疫检查点抑制剂的混合式治疗
CN118591557A (zh) 靶向tigit的抗原结合蛋白及其用途
HK1167325B (en) Antibodies against vascular endothelial growth factor receptor-1
HK1115302B (en) Antibodies against vascular endothelial growth factor receptor-1